Meijun Yu , Yue Li , Zhaojun Wang , Ping Han , Yanping Jiang , Wen Cui , Yijing Li , Lijie Tang , Shuo Jia , Hongzhe Zhao , Yingying Ma , Jiaxuan Li , Xiaona Wang
{"title":"Overcoming gastrointestinal mucosal barriers: Mechanistic innovations and technical advances in mucosal targeting strategies for animal oral vaccines","authors":"Meijun Yu , Yue Li , Zhaojun Wang , Ping Han , Yanping Jiang , Wen Cui , Yijing Li , Lijie Tang , Shuo Jia , Hongzhe Zhao , Yingying Ma , Jiaxuan Li , Xiaona Wang","doi":"10.1016/j.vetmic.2026.110983","DOIUrl":null,"url":null,"abstract":"<div><div>Infectious diseases caused by pathogenic microorganisms (such as <em>Escherichia coli</em>, <em>Avian influenza virus</em> (AIV), <em>Rotavirus</em>, etc.) that primarily invade through mucosal surfaces like the digestive tract and respiratory tract not only severely restrict the development of the livestock and poultry breeding industry, resulting in huge economic losses, but also threaten public health security due to the risk of cross-species transmission. Oral vaccines, by simulating natural infection routes to activate the mucosal immune system, have advantages such as ease of administration, wide applicability, and avoidance of injection stress, thus becoming an important means to prevent and control mucosal infectious diseases. However, due to the acidic environment of the gastrointestinal tract, degradation by digestive enzymes, and obstruction by mucosal barriers, the stability and immunogenicity of antigens are significantly reduced, which greatly limits the application of oral vaccines. Mucosal targeting strategy is the core technology to break through the above bottlenecks. Through antigen protection and sustained release, precise targeting of immune cells, and carrier adjuvant effect, it can efficiently activate synergistic responses between mucosal immunity (such as secretory immunoglobulin A (SIgA) production) and systemic immunity. This article systematically reviews the technological advances in mucosal targeting strategies for oral vaccines, including the dynamic process of vaccines <em>in vivo</em>, the biological barriers to be overcome, and specific targeting techniques for immune cells such as M cells and dendritic cells. Meanwhile, drawing on cutting-edge applications of drug targeting technology and artificial intelligence in antigen design, it provides theoretical references and research ideas for the construction of safe and efficient mucosal-targeted oral vaccines for animals.</div></div>","PeriodicalId":23551,"journal":{"name":"Veterinary microbiology","volume":"316 ","pages":"Article 110983"},"PeriodicalIF":2.8000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary microbiology","FirstCategoryId":"97","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0378113526001148","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Infectious diseases caused by pathogenic microorganisms (such as Escherichia coli, Avian influenza virus (AIV), Rotavirus, etc.) that primarily invade through mucosal surfaces like the digestive tract and respiratory tract not only severely restrict the development of the livestock and poultry breeding industry, resulting in huge economic losses, but also threaten public health security due to the risk of cross-species transmission. Oral vaccines, by simulating natural infection routes to activate the mucosal immune system, have advantages such as ease of administration, wide applicability, and avoidance of injection stress, thus becoming an important means to prevent and control mucosal infectious diseases. However, due to the acidic environment of the gastrointestinal tract, degradation by digestive enzymes, and obstruction by mucosal barriers, the stability and immunogenicity of antigens are significantly reduced, which greatly limits the application of oral vaccines. Mucosal targeting strategy is the core technology to break through the above bottlenecks. Through antigen protection and sustained release, precise targeting of immune cells, and carrier adjuvant effect, it can efficiently activate synergistic responses between mucosal immunity (such as secretory immunoglobulin A (SIgA) production) and systemic immunity. This article systematically reviews the technological advances in mucosal targeting strategies for oral vaccines, including the dynamic process of vaccines in vivo, the biological barriers to be overcome, and specific targeting techniques for immune cells such as M cells and dendritic cells. Meanwhile, drawing on cutting-edge applications of drug targeting technology and artificial intelligence in antigen design, it provides theoretical references and research ideas for the construction of safe and efficient mucosal-targeted oral vaccines for animals.
期刊介绍:
Veterinary Microbiology is concerned with microbial (bacterial, fungal, viral) diseases of domesticated vertebrate animals (livestock, companion animals, fur-bearing animals, game, poultry, fish) that supply food, other useful products or companionship. In addition, Microbial diseases of wild animals living in captivity, or as members of the feral fauna will also be considered if the infections are of interest because of their interrelation with humans (zoonoses) and/or domestic animals. Studies of antimicrobial resistance are also included, provided that the results represent a substantial advance in knowledge. Authors are strongly encouraged to read - prior to submission - the Editorials (''Scope or cope'' and ''Scope or cope II'') published previously in the journal. The Editors reserve the right to suggest submission to another journal for those papers which they feel would be more appropriate for consideration by that journal.
Original research papers of high quality and novelty on aspects of control, host response, molecular biology, pathogenesis, prevention, and treatment of microbial diseases of animals are published. Papers dealing primarily with immunology, epidemiology, molecular biology and antiviral or microbial agents will only be considered if they demonstrate a clear impact on a disease. Papers focusing solely on diagnostic techniques (such as another PCR protocol or ELISA) will not be published - focus should be on a microorganism and not on a particular technique. Papers only reporting microbial sequences, transcriptomics data, or proteomics data will not be considered unless the results represent a substantial advance in knowledge.
Drug trial papers will be considered if they have general application or significance. Papers on the identification of microorganisms will also be considered, but detailed taxonomic studies do not fall within the scope of the journal. Case reports will not be published, unless they have general application or contain novel aspects. Papers of geographically limited interest, which repeat what had been established elsewhere will not be considered. The readership of the journal is global.